Plain-English translation of NCT06238648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for patients with aggressive B-cell lymphoma who received CAR-T cell therapy (a type of immunotherapy using your own immune cells) but didn't achieve a complete remission. Half of the participants will receive the medication, while the other half will be monitored without it to see which approach works better.
CAR-T cell therapy is a powerful treatment, but it doesn't work completely for all patients with aggressive lymphomas. This study aims to find out whether adding this medication can help patients whose cancer didn't fully disappear after CAR-T therapy get better results.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to either receive the medication or be observed without it. If assigned to receive the medication, you'll get injections under your skin multiple times per month for up to 12 months, with the frequency decreasing over time. Both groups will have regular PET scans, blood tests, and biopsies to track how the lymphoma responds. You'll need to visit the clinic frequently at first, then less often as treatment progresses.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States